slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 226,441-226,470
Pages 10,126
Rows per page 30
Component
226,441-226,470 of 303,780
27
The slide uses a standard pharmaceutical pipeline table format, categorizing by clinical vs preclinical status and highlighting specific regulatory designations and trial results.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Market Sizing1 hit
29
The slide uses a visual wave/area chart metaphor to represent market segments and their respective valuations.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Market Sizing1 hit
30
Immix Biopharma | Investor Presentation Deck | 64 slidesImmix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
31
The slide uses a red dashed box to highlight the primary efficacy metrics for comparison.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
32
The chart uses a grouped bar structure to compare NXC-201 (green) against other therapies (blue/red) categorized by prior BCMA treatment status.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
33
The table compares NXC-201 against various CAR-T therapies, highlighting patient characteristics, efficacy (ORR, CR), and safety (ICANS, CRS) metrics.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
34
The slide uses a side-by-side comparison of two disease indications, showing clinical results, relevant competitor benchmarks, and market size.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
35
The chart demonstrates deepening clinical response over time for NXC-201 therapy.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
36
The table displays clinical trial data for NXC-201, specifically focusing on safety profiles and management interventions.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
37
The table highlights specific clinical safety metrics including onset and duration for CRS and ICANS, as well as the use of Tocilizumab and Dexamethasone.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
39
The slide features a scientific illustration of cellular structures, likely representing the drug's mechanism of action or target environment.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
41
Slide contains three distinct charts comparing IMX-110 against standard of care in mouse models.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
42
Includes a process flow diagram illustrating the mechanism of action of IMX-110 in tumor microenvironments.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
43
Includes survival curves (Kaplan-Meier style), median survival bar charts, and bioluminescence imaging of tumor activity.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
44
Immix Biopharma | Investor Presentation Deck | 64 slidesImmix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
45
The slide compares sarcoma patients against non-sarcoma patients using line charts for lesion size change and a bar chart for best percentage change.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
46
The bubble chart maps mPFS against patient treatment history; the table highlights poor outcomes and high toxicity across lines of therapy.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
47
The slide presents clinical data for a small sample size (n=4).Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
48
Shows two parallel clinical development tracks: monotherapy and combination with tislelizumab.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
49
Immix Biopharma | Investor Presentation Deck | 64 slidesImmix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
52
Includes a comparative size diagram of the drug vs IgG antibody and a Kaplan-Meier survival curve.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
53
Includes two distinct sets of preclinical charts (tumor volume and survival curves) with detailed methodology in footnotes.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
54
Includes multiple citations and diagrams illustrating the mechanism of action and clinical results.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
55
The slide uses a numbered list format to present key value propositions.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
56
Immix Biopharma | Investor Presentation Deck | 64 slidesImmix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
57
The slide uses a side-by-side comparison structure to explain two distinct proprietary platforms.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
58
The process flow is non-linear, moving left-to-right on the top row (1-5) and right-to-left on the bottom row (6-10).Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
59
Highlights NXC-201's lower fludarabine dose and compares infusion timing across therapies.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
60
The table compares four different therapies across four criteria categories: Prior lines of therapy, Toxicity recovery, ECOG, and Measurable disease.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
61
The slide highlights that NXC-201 has no exclusion for prior BCMA therapy, unlike the other listed treatments.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit